How Are Key Lymphoma Data From ASCO and EHA 2026 Shaping Treatment?

Rákkutatás · Lymphoma

Recent regulatory approvals of CAR T‑cell therapies and bispecific antibodies have significantly expanded frontline and relapsed‑refractory treatment options for follicular lymphoma.

Significant strides have been made in the treatment of follicular lymphoma, leading to improvements in long‑term patient outcomes. However, the disease’s heterogeneity presents challenges in selecting the optimal therapy at each stage of treatment. The expanding array of therapeutic options introduces new complexities, including making the right initial choice, sequencing treatments effectively, and redefining treatment goals. As the landscape evolves, there is a growing need to shift toward precision‑based treatment decisions, potentially guided by underlying disease biology. Here, we explore recent advancements in both upfront and relapsed‑/refractory treatment strategies, addressing considerations in therapy selection, and the current progress toward precision approaches with its potential to enhance decision‑making.

The expanding array of therapeutic options introduces new complexities, including making the right initial choice, sequencing treatments effectively, and redefining treatment goals. This underscores the need for precision‑based treatment decisions to improve long‑term outcomes in follicular lymphoma.

Bizonyítékszint: Megerősített klinikai bizonyíték. Több vagy erősebb humán vizsgálat támogatja.

Eredeti forrás

Kapcsolódó jelek